Shopping Cart 0
Cart Subtotal
USD 0

Antihyperlipidemic Drugs Market by Drug Class (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, and Combination): Global Opportunity Analysis and Industry Forecast, 2019-2026

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 5370

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 8995

Details

The global antihyperlipidemic drugs market accounted for USD 9,456 million in 2018, and is expected to reach USD 16,864 million by 2026, registering a CAGR of 7.5% from 2019 to 2026.

Lipids are defined as the organic compounds that are fatty acids. These fatty acids are essential and serve as building blocks of the cellular membranes in the living organisms. However, surge in level of lipids in the blood leads to their deposition in the arteries. This deposition of the lipids in the arteries leads to blockage, which in turn increases the risk of heart attacks. Therefore, the condition requires early detection and treatment. The treatment of hyperlipidemia is carried out using antihyperlipidemic drugs. Some of the antihyperlipidemic drugs available in the market include statins, bile acid sequestrants, cholesterol absorption inhibitors, and others.

The factors that contribute for the growth of the market include surge in sedentary lifestyle. Furthermore, rise in incidence of disorders related to distributed cholesterol levels in the blood also contributes to the growth of the antihyperlipidemic drugs market. Moreover, surge in awareness regarding complications related with hyperlipidemia is another major factor that fuels the growth of the market. However, high cost of the treatment hinders the market growth. Conversely, growth opportunities exhibited by emerging economies is expected to offer lucrative opportunities for the market growth during the forecast period.

The antihyperlipidemic drugs market size is studied based on segments, drug class and region, to provide a detailed assessment of the market. Based on drug class, the market is divided into statins, pcsk9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and combination. Based on region, the antihyperlipidemic drugs market size is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

This report entails a detailed quantitative analysis along with the current global antihyperlipidemic market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.

The market size and estimations are based on a comprehensive analysis of key developments in the industry.

A qualitative analysis based on innovative products facilitates strategic business planning.

The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments

By Drug Class

o Statins

o PCSK9 Inhibitors

o Bile Acid Sequestrants

o Cholesterol Absorption Inhibitors

o Fibric Acid Derivatives

o Combination

o Symptoms Check

By Region

o North America

U.S.

Canada

Mexico

o Europe

Germany

France

UK

Italy

Spain

Rest of Europe

o Asia-Pacific

Japan

China

India

Australia

South Korea

Rest of Asia-Pacific

o LAMEA

Brazil

Saudi Arabia

South Africa

Rest of LAMEA

List of key players profiled in the report:

Boehringer Ingelheim GmbH

Merck KGaA

Johnson and Johnson

Bayer AG

Pfizer, Inc.

Takeda Pharmaceutical Co., Ltd.

AstraZeneca plc,

READ MORE

Table Of Content

Scope

Chapter 1: Introduction

1.1. Report Description

1.2. Key Market Segments

1.2.1. List of Key Players Profiled In The Report

1.3. Research Methodology

1.3.1. Primary Research

1.3.2. Secondary Research

1.3.3. Analyst Tools And Models

Chapter 2: Executive Summary

2.1. Key Findings of The Study

2.2. Cxo Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope

3.2. Top Player Positioning

3.2.1. Top Investment Pockets

3.3. Key Forces Shaping Antihyperlipidemic Industry/Market

3.4. Market Dynamics

3.4.1. Drivers

3.4.1.1. Presence of Guidelines Recommending The Use of Statins

3.4.1.2. Surge In Healthcare Expenditure Worldwide

3.4.1.3. Rise In Prevalence of Hyperlipidemia Across The Globe

3.4.2. Restraint

3.4.2.1. Upcoming Patent Expirations of Drugs

3.4.3. Opportunity

3.4.3.1. High Growth Potential In Developing Economies

3.4.4. Impact Analyses

Chapter 4: Antihyperlipidemic Drugs Market, By Drug Class

4.1. Overview

4.1.1. Market Size And Forecast

4.2. Statins

4.2.1. Key Market Trends, Growth Factors, And Opportunities

4.2.2. Market Size And Forecast, By Region

4.2.3. Market Analysis By Country

4.3. Bile Acid Sequestrants

4.3.1. Key Market Trends, Growth Factors, And Opportunities

4.3.2. Market Size And Forecast, By Region

4.3.3. Market Analysis By Country

4.4. Cholesterol Absorption Inhibitors

4.4.1. Key Market Trends, Growth Factors, And Opportunities

4.4.2. Market Size And Forecast, By Region

4.4.3. Market Analysis By Country

4.5. Fibric Acid Derivatives

4.5.1. Key Market Trends, Growth Factors, And Opportunities

4.5.2. Market Size And Forecast, By Region

4.5.3. Market Analysis By Country

4.6. Pcsk9 Inhibitors

4.6.1. Key Market Trends, Growth Factors, And Opportunities

4.6.2. Market Size And Forecast, By Region

4.6.3. Market Analysis By Country

4.7. Combination

4.7.1. Key Market Trends, Growth Factors, And Opportunities

4.7.2. Market Size And Forecast, By Region

4.7.3. Market Analysis By Country

4.8. Others

4.8.1. Key Market Trends, Growth Factors, And Opportunities

4.8.2. Market Size And Forecast, By Region

4.8.3. Market Analysis By Country

Chapter 5: Antihyperlipidemic Drugs Market, By Region

5.1. Overview

5.1.1. Market Size And Forecast

5.2. North America

5.2.1. Key Market Trends And Opportunities

5.2.2. Market Analysis, By Country

5.2.2.1. U.S.

5.2.2.1.1. U.S. Market Size And Forecast, By Drug Class

5.2.2.2. Canada

5.2.2.2.1. Canada Market Size And Forecast, By Drug Class

5.2.2.3. Mexico

5.2.2.3.1. Mexico Market Size And Forecast, By Drug Class

5.2.3. North America Market Size And Forecast, By Drug Class

5.3. Europe

5.3.1. Key Market Trends And Opportunities

5.3.2. Market Analysis, By Country

5.3.2.1. Germany

5.3.2.1.1. Germany Market Size And Forecast, By Drug Class

5.3.2.2. France

5.3.2.2.1. France Market Size And Forecast, By Drug Class

5.3.2.3. Uk

5.3.2.3.1. Uk Market Size And Forecast, By Drug Class

5.3.2.4. Italy

5.3.2.4.1. Italy Market Size And Forecast, By Drug Class

5.3.2.5. Rest of Europe

5.3.2.5.1. Rest of Europe Market Size And Forecast, By Drug Class

5.3.3. Europe Market Size And Forecast, By Drug Class

5.4. Asia-Pacific

5.4.1. Key Market Trends And Opportunities

5.4.2. Market Analysis, By Country

5.4.2.1. Japan

5.4.2.1.1. Japan Market Size And Forecast, By Drug Class

5.4.2.2. China

5.4.2.2.1. China Market Size And Forecast, By Drug Class

5.4.2.3. India

5.4.2.3.1. India Market Size And Forecast, By Drug Class

5.4.2.4. Rest of Asia-Pacific

5.4.2.4.1. Rest of Asia-Pacific Market Size And Forecast, By Drug Class

5.4.3. Asia-Pacific Market Size And Forecast, By Drug Class

5.5. Lamea

5.5.1. Key Market Trends And Opportunities

5.5.2. Market Analysis, By Country

5.5.2.1. Brazil

5.5.2.1.1. Brazil Market Size And Forecast, By Drug Class

5.5.2.2. South Africa

5.5.2.2.1. South Africa Market Size And Forecast, By Drug Class

5.5.2.3. Saudi Arabia

5.5.2.3.1. Saudi Arabia Market Size And Forecast, By Drug Class

5.5.2.4. Rest of Lamea

5.5.2.4.1. Rest of Lamea Market Size And Forecast, By Drug Class

5.5.3. Lamea Market Size And Forecast, By Drug Class

Chapter 6: Company Profiles

6.1. Abbvie Inc.

6.1.1. Company Overview

6.1.2. Company Snapshot

6.1.3. Operating Business Segments

6.1.4. Product Portfolio

6.1.5. Business Performance

6.2. Amgen Inc.

6.2.1. Company Overview

6.2.2. Company Snapshot

6.2.3. Operating Business Segments

6.2.4. Product Portfolio

6.2.5. Business Performance

6.2.6. Key Strategic Moves And Developments

6.3. Astrazeneca Plc

6.3.1. Company Overview

6.3.2. Company Snapshot

6.3.3. Operating Business Segments

6.3.4. Product Portfolio

6.3.5. Business Performance

6.4. Bristol-Myers Squibb Company

6.4.1. Company Overview

6.4.2. Company Snapshot

6.4.3. Operating Business Segments

6.4.4. Product Portfolio

6.4.5. Business Performance

6.5. Daiichi Sankyo Company, Limited

6.5.1. Company Overview

6.5.2. Operating Business Segments

6.5.3. Product Portfolio

6.5.4. Business Performance

6.6. Dr. Reddy'S Laboratories Ltd

6.6.1. Company Overview

6.6.2. Company Snapshot

6.6.3. Operating Business Segments

6.6.4. Product Portfolio

6.6.5. Business Performance

6.7. Merck & Co., Inc

6.7.1. Company Overview

6.7.2. Company Snapshot

6.7.3. Operating Business Segments

6.7.4. Product Portfolio

6.7.5. Business Performance

6.8. Mylan N.V

6.8.1. Company Overview

6.8.2. Company Snapshot

6.8.3. Operating Business Segments

6.8.4. Product Portfolio

6.8.5. Business Performance

6.9. Pfizer Inc.

6.9.1. Company Overview

6.9.2. Company Snapshot

6.9.3. Operating Business Segments

6.9.4. Product Portfolio

6.9.5. Business Performance

6.10. Sanofi S.A.

6.10.1. Company Overview

6.10.2. Operating Business Segments

6.10.3. Product Portfolio

6.10.4. Business Performance

6.10.5. Key Strategic Moves And Developments


List Of Figure

List of Figures

Figure 01. Global Antihyperlipidemic Drugs Market Segmentation

Figure 02. Top Player Positioning, 2018

Figure 03. Top Investment Pockets

Figure 04. Moderate Bargaining Power of Supplier

Figure 05. Low Bargaining Power of Buyers

Figure 06. Low Threat of Substitutes

Figure 07. High Intensity of Rivalry

Figure 08. Low Threat of New Entrant

Figure 09. Impact Analyses, Antihyperlipidemic Drugs Market

Figure 10. Comparative Share Analysis of Statins Antihyperlipidemic Drugs Market, By Country, 2018 & 2026 (%)

Figure 11. Comparative Share Analysis of Bile Acid Sequestrants Antihyperlipidemic Drugs Market, By Country, 2018 & 2026 (%)

Figure 12. Comparative Share Analysis of Cholesterol Absorption Inhibitors Antihyperlipidemic Drugs Market, By Country, 2018 & 2026 (%)

Figure 13. Comparative Share Analysis of Fibric Acid Derivatives Antihyperlipidemic Drugs Market, By Country, 2018 & 2026 (%)

Figure 14. Comparative Share Analysis of Pcsk9 Inhibitors Antihyperlipidemic Drugs Market, By Country, 2018 & 2026 (%)

Figure 15. Comparative Share Analysis of Combination Antihyperlipidemic Drugs Market, By Country, 2018 & 2026 (%)

Figure 16. Comparative Share Analysis of Others Antihyperlipidemic Drugs Market, By Country, 2018 & 2026 (%)

Figure 17. U.S. Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 18. Canada Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 19. Mexico Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 20. Germany Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 21. France Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 22. Uk Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 23. Italy Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 24. Rest of Europe Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 25. Japan Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 26. China Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 27. India Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 28. Rest of Asia-Pacific Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 29. Brazil Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 30. South Africa Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 31. Saudi Arabia Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 32. Rest of Lamea Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 33. Abbvie: Net Sales, 2016-2018 (USD Million)

Figure 34. Abbvie: Revenue Share By Region, 2018(%)

Figure 35. Amgen: Net Sales, 2016-2018 (USD Million)

Figure 36. Amgen: Revenue Share By Region, 2018(%)

Figure 37. Astrazeneca: Net Sales, 2016-2018 (USD Million)

Figure 38. Astrazeneca: Revenue Share By Region, 2018(%)

Figure 39. Bms: Net Sales, 2016-2018 (USD Million)

Figure 40. Bms: Revenue Share By Region, 2018(%)

Figure 41. Daiichi-Sankyo: Net Sales, 2016-2018 (USD Million)

Figure 42. Daiichi-Sankyo: Revenue Share By Segment, 2018 (%)

Figure 43. Daiichi-Sankyo: Revenue Share By Region, 2018(%)

Figure 44. Dr. Reddy'S: Net Sales, 2016-2018 (USD Million)

Figure 45. Dr. Reddy'S: Revenue Share By Segment, 2018 (%)

Figure 46. Dr. Reddy'S: Revenue Share By Region, 2018(%)

Figure 47. Merck: Net Sales, 2016-2018 (USD Million)

Figure 48. Merck: Revenue Share By Segment, 2018 (%)

Figure 49. Merck: Revenue Share By Region, 2018(%)

Figure 50. Mylan: Net Sales, 2016-2018 (USD Million)

Figure 51. Mylan: Revenue Share By Geography, 2018 (%)

Figure 52. Pfizer: Net Sales, 2016-2018 (USD Million)

Figure 53. Pfizer: Revenue Share By Segment, 2018 (%)

Figure 54. Pfizer: Revenue Share By Region, 2018(%)

Figure 55. Sanofi: Net Sales, 2016-2018 (USD Million)

Figure 56. Sanofi: Revenue Share By Segment, 2018 (%)

Figure 57. Sanofi: Revenue Share By Region, 2018(%)


List Of Table

List of Tables

Table 01. Global Antihyperlipidemic Drugs Market, By Drug Class, 2018-2026 (USD Million )

Table 02. Statins Antihyperlipidemic Drugs Market, By Region, 2018-2026 (USD Million)

Table 03. Bile Acid Sequestrants Antihyperlipidemic Drugs Market, By Region, 2018-2026 (USD Million)

Table 04. Cholesterol Absorption Inhibitors Antihyperlipidemic Drugs Market, By Region, 2018-2026 (USD Million)

Table 05. Fibric Acid Derivatives Antihyperlipidemic Drugs Market, By Region, 2018-2026 (USD Million)

Table 06. Pcsk9 Inhibitors Antihyperlipidemic Drugs Market, By Region, 2018-2026 (USD Million)

Table 07. Combination Antihyperlipidemic Drugs Market, By Region, 2018-2026 (USD Million)

Table 08. Others Antihyperlipidemic Drugs Market, By Region, 2018-2026 (USD Million)

Table 09. Antihyperlipidemic Drugs Market, By Region, 2018-2026 (USD Million )

Table 10. North America Antihyperlipidemic Drugs Market Revenue, By Country, 2019-2026 (USD Million)

Table 11. U.S. Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 12. Canada Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 13. Mexico Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 14. North America Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026(USD Million)

Table 15. Europe Antihyperlipidemic Drugs Market Revenue, By Country, 2019-2026 (USD Million)

Table 16. Germany Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 17. France Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 18. Uk Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 19. Italy Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 20. Rest of Europe Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 21. Europe Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026(USD Million)

Table 22. Asia-Pacific Antihyperlipidemic Drugs Market Revenue, By Country, 2019-2026 (USD Million)

Table 23. Japan Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 24. China Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 25. India Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 26. Rest of Asia-Pacific Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 27. Asia-Pacific Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026(USD Million)

Table 28. Lamea Antihyperlipidemic Drugs Market Revenue, By Country, 2019-2026 (USD Million)

Table 29. Brazil Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 30. South Africa Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 31. Saudi Arabia Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 32. Rest of Lamea Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 33. Lamea Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026(USD Million)

Table 34. Abbvie: Company Snapshot

Table 35. Abbvie: Operating Business Segments

Table 36. Abbvie: Product Portfolio

Table 37. Amgen: Company Snapshot

Table 38. Amgen: Product Business Segment

Table 39. Amgen: Product Portfolio

Table 40. Astrazeneca: Company Snapshot

Table 41. Astrazeneca: Operating Business Segments

Table 42. Astrazeneca: Product Portfolio

Table 43. Bms: Company Snapshot

Table 44. Bms: Operating Segments

Table 45. Bms: Product Portfolio

Table 46. Daiichi-Sankyo.: Company Snapshot

Table 47. Daiichi-Sankyo.: Operating Business Segments

Table 48. Daiichi-Sankyo.: Product Portfolio

Table 49. Dr.Reddy'S: Company Snapshot

Table 50. Dr. Reddy'S: Operating Business Segments

Table 51. Dr. Reddy'S: Product Portfolio

Table 52. Merck: Company Snapshot

Table 53. Merck: Operating Segments

Table 54. Merck: Product Portfolio

Table 55. Mylan: Company Snapshot

Table 56. Mylan: Operating Segments

Table 57. Mylan: Product Portfolio

Table 58. Pfizer: Company Snapshot

Table 59. Pfizer: Operating Segments

Table 60. Pfizer: Product Portfolio

Table 61. Sanofi: Company Snapshot

Table 62. Sanofi: Product Portfolio

Licence Rights

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Boehringer Ingelheim GmbH, Merck KGaA, Johnson and Johnson, Bayer AG, Pfizer, Inc. Takeda Pharmaceutical Co., Ltd., AstraZeneca plc, Daiichi Sankyo Company, Sanofi S.A., and Novartis International AG.

Company Profile

Company Profile Title

The global antihyperlipidemic drugs market accounted for USD 9,456 million in 2018, and is expected to reach USD 16,864 million by 2026, registering a CAGR of 7.5% from 2019 to 2026.

Lipids are defined as the organic compounds that are fatty acids. These fatty acids are essential and serve as building blocks of the cellular membranes in the living organisms. However, surge in level of lipids in the blood leads to their deposition in the arteries. This deposition of the lipids in the arteries leads to blockage, which in turn increases the risk of heart attacks. Therefore, the condition requires early detection and treatment. The treatment of hyperlipidemia is carried out using antihyperlipidemic drugs. Some of the antihyperlipidemic drugs available in the market include statins, bile acid sequestrants, cholesterol absorption inhibitors, and others.

The factors that contribute for the growth of the market include surge in sedentary lifestyle. Furthermore, rise in incidence of disorders related to distributed cholesterol levels in the blood also contributes to the growth of the antihyperlipidemic drugs market. Moreover, surge in awareness regarding complications related with hyperlipidemia is another major factor that fuels the growth of the market. However, high cost of the treatment hinders the market growth. Conversely, growth opportunities exhibited by emerging economies is expected to offer lucrative opportunities for the market growth during the forecast period.

The antihyperlipidemic drugs market size is studied based on segments, drug class and region, to provide a detailed assessment of the market. Based on drug class, the market is divided into statins, pcsk9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and combination. Based on region, the antihyperlipidemic drugs market size is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

This report entails a detailed quantitative analysis along with the current global antihyperlipidemic market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.

The market size and estimations are based on a comprehensive analysis of key developments in the industry.

A qualitative analysis based on innovative products facilitates strategic business planning.

The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments

By Drug Class

o Statins

o PCSK9 Inhibitors

o Bile Acid Sequestrants

o Cholesterol Absorption Inhibitors

o Fibric Acid Derivatives

o Combination

o Symptoms Check

By Region

o North America

U.S.

Canada

Mexico

o Europe

Germany

France

UK

Italy

Spain

Rest of Europe

o Asia-Pacific

Japan

China

India

Australia

South Korea

Rest of Asia-Pacific

o LAMEA

Brazil

Saudi Arabia

South Africa

Rest of LAMEA

List of key players profiled in the report:

Boehringer Ingelheim GmbH

Merck KGaA

Johnson and Johnson

Bayer AG

Pfizer, Inc.

Takeda Pharmaceutical Co., Ltd.

AstraZeneca plc,

READ MORE

Scope

Chapter 1: Introduction

1.1. Report Description

1.2. Key Market Segments

1.2.1. List of Key Players Profiled In The Report

1.3. Research Methodology

1.3.1. Primary Research

1.3.2. Secondary Research

1.3.3. Analyst Tools And Models

Chapter 2: Executive Summary

2.1. Key Findings of The Study

2.2. Cxo Perspective

Chapter 3: Market Overview

3.1. Market Definition And Scope

3.2. Top Player Positioning

3.2.1. Top Investment Pockets

3.3. Key Forces Shaping Antihyperlipidemic Industry/Market

3.4. Market Dynamics

3.4.1. Drivers

3.4.1.1. Presence of Guidelines Recommending The Use of Statins

3.4.1.2. Surge In Healthcare Expenditure Worldwide

3.4.1.3. Rise In Prevalence of Hyperlipidemia Across The Globe

3.4.2. Restraint

3.4.2.1. Upcoming Patent Expirations of Drugs

3.4.3. Opportunity

3.4.3.1. High Growth Potential In Developing Economies

3.4.4. Impact Analyses

Chapter 4: Antihyperlipidemic Drugs Market, By Drug Class

4.1. Overview

4.1.1. Market Size And Forecast

4.2. Statins

4.2.1. Key Market Trends, Growth Factors, And Opportunities

4.2.2. Market Size And Forecast, By Region

4.2.3. Market Analysis By Country

4.3. Bile Acid Sequestrants

4.3.1. Key Market Trends, Growth Factors, And Opportunities

4.3.2. Market Size And Forecast, By Region

4.3.3. Market Analysis By Country

4.4. Cholesterol Absorption Inhibitors

4.4.1. Key Market Trends, Growth Factors, And Opportunities

4.4.2. Market Size And Forecast, By Region

4.4.3. Market Analysis By Country

4.5. Fibric Acid Derivatives

4.5.1. Key Market Trends, Growth Factors, And Opportunities

4.5.2. Market Size And Forecast, By Region

4.5.3. Market Analysis By Country

4.6. Pcsk9 Inhibitors

4.6.1. Key Market Trends, Growth Factors, And Opportunities

4.6.2. Market Size And Forecast, By Region

4.6.3. Market Analysis By Country

4.7. Combination

4.7.1. Key Market Trends, Growth Factors, And Opportunities

4.7.2. Market Size And Forecast, By Region

4.7.3. Market Analysis By Country

4.8. Others

4.8.1. Key Market Trends, Growth Factors, And Opportunities

4.8.2. Market Size And Forecast, By Region

4.8.3. Market Analysis By Country

Chapter 5: Antihyperlipidemic Drugs Market, By Region

5.1. Overview

5.1.1. Market Size And Forecast

5.2. North America

5.2.1. Key Market Trends And Opportunities

5.2.2. Market Analysis, By Country

5.2.2.1. U.S.

5.2.2.1.1. U.S. Market Size And Forecast, By Drug Class

5.2.2.2. Canada

5.2.2.2.1. Canada Market Size And Forecast, By Drug Class

5.2.2.3. Mexico

5.2.2.3.1. Mexico Market Size And Forecast, By Drug Class

5.2.3. North America Market Size And Forecast, By Drug Class

5.3. Europe

5.3.1. Key Market Trends And Opportunities

5.3.2. Market Analysis, By Country

5.3.2.1. Germany

5.3.2.1.1. Germany Market Size And Forecast, By Drug Class

5.3.2.2. France

5.3.2.2.1. France Market Size And Forecast, By Drug Class

5.3.2.3. Uk

5.3.2.3.1. Uk Market Size And Forecast, By Drug Class

5.3.2.4. Italy

5.3.2.4.1. Italy Market Size And Forecast, By Drug Class

5.3.2.5. Rest of Europe

5.3.2.5.1. Rest of Europe Market Size And Forecast, By Drug Class

5.3.3. Europe Market Size And Forecast, By Drug Class

5.4. Asia-Pacific

5.4.1. Key Market Trends And Opportunities

5.4.2. Market Analysis, By Country

5.4.2.1. Japan

5.4.2.1.1. Japan Market Size And Forecast, By Drug Class

5.4.2.2. China

5.4.2.2.1. China Market Size And Forecast, By Drug Class

5.4.2.3. India

5.4.2.3.1. India Market Size And Forecast, By Drug Class

5.4.2.4. Rest of Asia-Pacific

5.4.2.4.1. Rest of Asia-Pacific Market Size And Forecast, By Drug Class

5.4.3. Asia-Pacific Market Size And Forecast, By Drug Class

5.5. Lamea

5.5.1. Key Market Trends And Opportunities

5.5.2. Market Analysis, By Country

5.5.2.1. Brazil

5.5.2.1.1. Brazil Market Size And Forecast, By Drug Class

5.5.2.2. South Africa

5.5.2.2.1. South Africa Market Size And Forecast, By Drug Class

5.5.2.3. Saudi Arabia

5.5.2.3.1. Saudi Arabia Market Size And Forecast, By Drug Class

5.5.2.4. Rest of Lamea

5.5.2.4.1. Rest of Lamea Market Size And Forecast, By Drug Class

5.5.3. Lamea Market Size And Forecast, By Drug Class

Chapter 6: Company Profiles

6.1. Abbvie Inc.

6.1.1. Company Overview

6.1.2. Company Snapshot

6.1.3. Operating Business Segments

6.1.4. Product Portfolio

6.1.5. Business Performance

6.2. Amgen Inc.

6.2.1. Company Overview

6.2.2. Company Snapshot

6.2.3. Operating Business Segments

6.2.4. Product Portfolio

6.2.5. Business Performance

6.2.6. Key Strategic Moves And Developments

6.3. Astrazeneca Plc

6.3.1. Company Overview

6.3.2. Company Snapshot

6.3.3. Operating Business Segments

6.3.4. Product Portfolio

6.3.5. Business Performance

6.4. Bristol-Myers Squibb Company

6.4.1. Company Overview

6.4.2. Company Snapshot

6.4.3. Operating Business Segments

6.4.4. Product Portfolio

6.4.5. Business Performance

6.5. Daiichi Sankyo Company, Limited

6.5.1. Company Overview

6.5.2. Operating Business Segments

6.5.3. Product Portfolio

6.5.4. Business Performance

6.6. Dr. Reddy'S Laboratories Ltd

6.6.1. Company Overview

6.6.2. Company Snapshot

6.6.3. Operating Business Segments

6.6.4. Product Portfolio

6.6.5. Business Performance

6.7. Merck & Co., Inc

6.7.1. Company Overview

6.7.2. Company Snapshot

6.7.3. Operating Business Segments

6.7.4. Product Portfolio

6.7.5. Business Performance

6.8. Mylan N.V

6.8.1. Company Overview

6.8.2. Company Snapshot

6.8.3. Operating Business Segments

6.8.4. Product Portfolio

6.8.5. Business Performance

6.9. Pfizer Inc.

6.9.1. Company Overview

6.9.2. Company Snapshot

6.9.3. Operating Business Segments

6.9.4. Product Portfolio

6.9.5. Business Performance

6.10. Sanofi S.A.

6.10.1. Company Overview

6.10.2. Operating Business Segments

6.10.3. Product Portfolio

6.10.4. Business Performance

6.10.5. Key Strategic Moves And Developments


List Of Figure

List of Figures

Figure 01. Global Antihyperlipidemic Drugs Market Segmentation

Figure 02. Top Player Positioning, 2018

Figure 03. Top Investment Pockets

Figure 04. Moderate Bargaining Power of Supplier

Figure 05. Low Bargaining Power of Buyers

Figure 06. Low Threat of Substitutes

Figure 07. High Intensity of Rivalry

Figure 08. Low Threat of New Entrant

Figure 09. Impact Analyses, Antihyperlipidemic Drugs Market

Figure 10. Comparative Share Analysis of Statins Antihyperlipidemic Drugs Market, By Country, 2018 & 2026 (%)

Figure 11. Comparative Share Analysis of Bile Acid Sequestrants Antihyperlipidemic Drugs Market, By Country, 2018 & 2026 (%)

Figure 12. Comparative Share Analysis of Cholesterol Absorption Inhibitors Antihyperlipidemic Drugs Market, By Country, 2018 & 2026 (%)

Figure 13. Comparative Share Analysis of Fibric Acid Derivatives Antihyperlipidemic Drugs Market, By Country, 2018 & 2026 (%)

Figure 14. Comparative Share Analysis of Pcsk9 Inhibitors Antihyperlipidemic Drugs Market, By Country, 2018 & 2026 (%)

Figure 15. Comparative Share Analysis of Combination Antihyperlipidemic Drugs Market, By Country, 2018 & 2026 (%)

Figure 16. Comparative Share Analysis of Others Antihyperlipidemic Drugs Market, By Country, 2018 & 2026 (%)

Figure 17. U.S. Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 18. Canada Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 19. Mexico Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 20. Germany Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 21. France Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 22. Uk Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 23. Italy Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 24. Rest of Europe Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 25. Japan Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 26. China Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 27. India Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 28. Rest of Asia-Pacific Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 29. Brazil Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 30. South Africa Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 31. Saudi Arabia Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 32. Rest of Lamea Antihyperlipidemic Drugs Market, 2018-2026 (USD Million)

Figure 33. Abbvie: Net Sales, 2016-2018 (USD Million)

Figure 34. Abbvie: Revenue Share By Region, 2018(%)

Figure 35. Amgen: Net Sales, 2016-2018 (USD Million)

Figure 36. Amgen: Revenue Share By Region, 2018(%)

Figure 37. Astrazeneca: Net Sales, 2016-2018 (USD Million)

Figure 38. Astrazeneca: Revenue Share By Region, 2018(%)

Figure 39. Bms: Net Sales, 2016-2018 (USD Million)

Figure 40. Bms: Revenue Share By Region, 2018(%)

Figure 41. Daiichi-Sankyo: Net Sales, 2016-2018 (USD Million)

Figure 42. Daiichi-Sankyo: Revenue Share By Segment, 2018 (%)

Figure 43. Daiichi-Sankyo: Revenue Share By Region, 2018(%)

Figure 44. Dr. Reddy'S: Net Sales, 2016-2018 (USD Million)

Figure 45. Dr. Reddy'S: Revenue Share By Segment, 2018 (%)

Figure 46. Dr. Reddy'S: Revenue Share By Region, 2018(%)

Figure 47. Merck: Net Sales, 2016-2018 (USD Million)

Figure 48. Merck: Revenue Share By Segment, 2018 (%)

Figure 49. Merck: Revenue Share By Region, 2018(%)

Figure 50. Mylan: Net Sales, 2016-2018 (USD Million)

Figure 51. Mylan: Revenue Share By Geography, 2018 (%)

Figure 52. Pfizer: Net Sales, 2016-2018 (USD Million)

Figure 53. Pfizer: Revenue Share By Segment, 2018 (%)

Figure 54. Pfizer: Revenue Share By Region, 2018(%)

Figure 55. Sanofi: Net Sales, 2016-2018 (USD Million)

Figure 56. Sanofi: Revenue Share By Segment, 2018 (%)

Figure 57. Sanofi: Revenue Share By Region, 2018(%)


List Of Table

List of Tables

Table 01. Global Antihyperlipidemic Drugs Market, By Drug Class, 2018-2026 (USD Million )

Table 02. Statins Antihyperlipidemic Drugs Market, By Region, 2018-2026 (USD Million)

Table 03. Bile Acid Sequestrants Antihyperlipidemic Drugs Market, By Region, 2018-2026 (USD Million)

Table 04. Cholesterol Absorption Inhibitors Antihyperlipidemic Drugs Market, By Region, 2018-2026 (USD Million)

Table 05. Fibric Acid Derivatives Antihyperlipidemic Drugs Market, By Region, 2018-2026 (USD Million)

Table 06. Pcsk9 Inhibitors Antihyperlipidemic Drugs Market, By Region, 2018-2026 (USD Million)

Table 07. Combination Antihyperlipidemic Drugs Market, By Region, 2018-2026 (USD Million)

Table 08. Others Antihyperlipidemic Drugs Market, By Region, 2018-2026 (USD Million)

Table 09. Antihyperlipidemic Drugs Market, By Region, 2018-2026 (USD Million )

Table 10. North America Antihyperlipidemic Drugs Market Revenue, By Country, 2019-2026 (USD Million)

Table 11. U.S. Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 12. Canada Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 13. Mexico Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 14. North America Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026(USD Million)

Table 15. Europe Antihyperlipidemic Drugs Market Revenue, By Country, 2019-2026 (USD Million)

Table 16. Germany Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 17. France Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 18. Uk Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 19. Italy Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 20. Rest of Europe Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 21. Europe Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026(USD Million)

Table 22. Asia-Pacific Antihyperlipidemic Drugs Market Revenue, By Country, 2019-2026 (USD Million)

Table 23. Japan Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 24. China Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 25. India Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 26. Rest of Asia-Pacific Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 27. Asia-Pacific Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026(USD Million)

Table 28. Lamea Antihyperlipidemic Drugs Market Revenue, By Country, 2019-2026 (USD Million)

Table 29. Brazil Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 30. South Africa Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 31. Saudi Arabia Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 32. Rest of Lamea Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026 (USD Million)

Table 33. Lamea Antihyperlipidemic Drugs Market Revenue, By Drug Class, 2019-2026(USD Million)

Table 34. Abbvie: Company Snapshot

Table 35. Abbvie: Operating Business Segments

Table 36. Abbvie: Product Portfolio

Table 37. Amgen: Company Snapshot

Table 38. Amgen: Product Business Segment

Table 39. Amgen: Product Portfolio

Table 40. Astrazeneca: Company Snapshot

Table 41. Astrazeneca: Operating Business Segments

Table 42. Astrazeneca: Product Portfolio

Table 43. Bms: Company Snapshot

Table 44. Bms: Operating Segments

Table 45. Bms: Product Portfolio

Table 46. Daiichi-Sankyo.: Company Snapshot

Table 47. Daiichi-Sankyo.: Operating Business Segments

Table 48. Daiichi-Sankyo.: Product Portfolio

Table 49. Dr.Reddy'S: Company Snapshot

Table 50. Dr. Reddy'S: Operating Business Segments

Table 51. Dr. Reddy'S: Product Portfolio

Table 52. Merck: Company Snapshot

Table 53. Merck: Operating Segments

Table 54. Merck: Product Portfolio

Table 55. Mylan: Company Snapshot

Table 56. Mylan: Operating Segments

Table 57. Mylan: Product Portfolio

Table 58. Pfizer: Company Snapshot

Table 59. Pfizer: Operating Segments

Table 60. Pfizer: Product Portfolio

Table 61. Sanofi: Company Snapshot

Table 62. Sanofi: Product Portfolio

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Boehringer Ingelheim GmbH, Merck KGaA, Johnson and Johnson, Bayer AG, Pfizer, Inc. Takeda Pharmaceutical Co., Ltd., AstraZeneca plc, Daiichi Sankyo Company, Sanofi S.A., and Novartis International AG.